Literature DB >> 25701959

Liver disease in the morbidly obese: a review of 1000 consecutive patients undergoing weight loss surgery.

Michael Subichin1, Jesse Clanton1, Marta Makuszewski1, Ashley Bohon1, John G Zografakis1, Adrian Dan2.   

Abstract

BACKGROUND: Liver disease among the morbidly obese is increasingly prevalent, contributing to significant morbidity. Obesity-related liver pathologies including nonalcoholic steatohepatitis (NASH) have become a leading cause for liver transplant. However, risk factors for developing severe liver disease in the morbidly obese remain unknown. The objective of this study was to determine the frequency of abnormal liver pathology and any relationship to patient-related factors.
METHODS: One thousand consecutive patients undergoing weight loss surgery were reviewed. All patients had a liver biopsy at the time of surgery. Frequency of benign pathology, steatosis, NASH, and fibrosis on pathologic examination of liver biopsy specimens were recorded. Pathologic findings were compared and analyzed to age and body mass index (BMI) of all patients.
RESULTS: All patients in the study population had a BMI>35 kg/m2. Of these patients, 80.2% had liver disease related to obesity on pathology, including 65.9% with steatosis (grade 1-3), and 14.3% with NASH and/or fibrosis. Mean BMI of patients with liver disease was 48.1 compared to a BMI of 47.7 with benign pathology (P=.523). Mean age of patients with and without abnormal pathology was 48.3 and 47.3, respectively (P=.294).
CONCLUSION: Liver disease is highly prevalent in the obese, but is not associated with increased age or BMI. Although all morbidly obese patients appear at significant risk for developing severe liver pathology, further risk factors are unknown.
Copyright © 2015. Published by Elsevier Inc.

Entities:  

Keywords:  Liver disease; Morbid obesity; NASH; Nonalcoholic steatohepatitis

Mesh:

Year:  2014        PMID: 25701959     DOI: 10.1016/j.soard.2014.06.015

Source DB:  PubMed          Journal:  Surg Obes Relat Dis        ISSN: 1550-7289            Impact factor:   4.734


  24 in total

Review 1.  AGA Clinical Practice Update on Screening and Surveillance for Hepatocellular Carcinoma in Patients With Nonalcoholic Fatty Liver Disease: Expert Review.

Authors:  Rohit Loomba; Joseph K Lim; Heather Patton; Hashem B El-Serag
Journal:  Gastroenterology       Date:  2020-01-30       Impact factor: 22.682

Review 2.  Monitoring of Liver Function Tests after Roux-en-Y Gastric Bypass: An Examination of Evidence Base.

Authors:  Kamal K Mahawar; Chetan Parmar; Yitka Graham; Nimantha De Alwis; William R J Carr; Neil Jennings; Peter K Small
Journal:  Obes Surg       Date:  2016-10       Impact factor: 4.129

3.  The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease.

Authors:  Mohammed Eslam; Shiv K Sarin; Vincent Wai-Sun Wong; Jian-Gao Fan; Takumi Kawaguchi; Sang Hoon Ahn; Ming-Hua Zheng; Gamal Shiha; Yusuf Yilmaz; Rino Gani; Shahinul Alam; Yock Young Dan; Jia-Horng Kao; Saeed Hamid; Ian Homer Cua; Wah-Kheong Chan; Diana Payawal; Soek-Siam Tan; Tawesak Tanwandee; Leon A Adams; Manoj Kumar; Masao Omata; Jacob George
Journal:  Hepatol Int       Date:  2020-10-01       Impact factor: 6.047

4.  Evolution of Liver Steatosis Quantified by MR Imaging and MR Spectroscopy, in Morbidly Obese Patients Undergoing Sleeve Gastrectomy: Short-Term Outcomes.

Authors:  María Engracia Alsina; Jaime Ruiz-Tovar; Angela Bernabeu
Journal:  Obes Surg       Date:  2017-07       Impact factor: 4.129

Review 5.  Routine Liver Biopsy During Bariatric Surgery: an Analysis of Evidence Base.

Authors:  Kamal K Mahawar; Chetan Parmar; Yitka Graham; Ayman Abouleid; William R J Carr; Neil Jennings; Norbert Schroeder; Peter K Small
Journal:  Obes Surg       Date:  2016-01       Impact factor: 4.129

6.  Hepatocyte Nicotinamide Adenine Dinucleotide Phosphate Reduced Oxidase 4 Regulates Stress Signaling, Fibrosis, and Insulin Sensitivity During Development of Steatohepatitis in Mice.

Authors:  Ahmed Bettaieb; Joy X Jiang; Yu Sasaki; Tzu-I Chao; Zsofia Kiss; Xiangling Chen; Jijing Tian; Masato Katsuyama; Chihiro Yabe-Nishimura; Yannan Xi; Cedric Szyndralewiez; Kathrin Schröder; Ajay Shah; Ralph P Brandes; Fawaz G Haj; Natalie J Török
Journal:  Gastroenterology       Date:  2015-04-14       Impact factor: 22.682

Review 7.  Metabolic-associated Fatty Liver Disease (MAFLD): A Multi-systemic Disease Beyond the Liver.

Authors:  Eda Kaya; Yusuf Yilmaz
Journal:  J Clin Transl Hepatol       Date:  2021-10-19

8.  Physiologically-Based Pharmacokinetic Model of Morphine and Morphine-3-Glucuronide in Nonalcoholic Steatohepatitis.

Authors:  Noora Sjöstedt; Sibylle Neuhoff; Kim L R Brouwer
Journal:  Clin Pharmacol Ther       Date:  2020-11-06       Impact factor: 6.875

Review 9.  Non-Alcoholic Fatty Liver Disease: Metabolic, Genetic, Epigenetic and Environmental Risk Factors.

Authors:  Oriol Juanola; Sebastián Martínez-López; Rubén Francés; Isabel Gómez-Hurtado
Journal:  Int J Environ Res Public Health       Date:  2021-05-14       Impact factor: 3.390

10.  Therapeutic effects of sleeve gastrectomy for non-alcoholic steatohepatitis estimated by paired liver biopsy in morbidly obese Japanese patients.

Authors:  Eisuke Murakami; Takashi Nakahara; Akira Hiramatsu; Kei Morio; Hatsue Fujino; Masami Yamauchi; Tomokazu Kawaoka; Masataka Tsuge; Michio Imamura; Hiroshi Aikata; Kenichi Fudeyasu; Yuki Nakashima; Daisuke Iwaki; Daichi Jodai; Toshikazu Ohigashi; Yui Nishimura; Yusuke Minamoto; Akiko Nagao; Masayasu Yoneda; Yoshihiro Saeki; Kazuaki Tanabe; Hideki Ohdan; Kazuaki Chayama
Journal:  Medicine (Baltimore)       Date:  2021-07-02       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.